Abstract:Significance Statement The main target antigen of autoantibodies against glomerular basement membrane (GBM) in Goodpasture disease is the noncollagenous domain 1 of the α 3 chain ( α 3NC1) of type IV collagen. The authors previously identified a nephritogenic peptide, P14 ( α 3 127–148 ). In this study, they designed a modified peptide with one amino acid substitution in its core motif, replacing a pathogenic residue with a nonpathogenic one. Administering this modified peptide to rats with α 3-P14–induced anti-GBM GN reduced inflammatory responses and crescent formation in the kidneys through inhibition of α 3-P14 binding to antibodies and MHC II molecules, as well as through modulation of T cells, including inhibiting α 3-P14–specific T cell proliferation and abating Th17 cell differentiation. This peptide modification approach may offer insights into treating Goodpasture disease and other autoimmune kidney disorders. Background In Goodpasture disease, the noncollagenous domain 1 of the α 3 chain ( α 3NC1) of type IV collagen is the main target antigen of antibodies against glomerular basement membrane (GBM). We previously identified a nephritogenic epitope, P14 ( α 3 127–148 ), that could induce crescentic nephritis in WKY rats, and defined its core motif. Designing a modified peptide, replacing critical pathogenic residues with nonpathogenic ones (on the basis of homologous regions in α 1NC1 chain of type IV collagen, known to be nonpathogenic), might provide a therapeutic option for anti-GBM GN. Methods We synthesized a modified peptide, replacing a single amino acid, and injected it into α 3-P14–immunized rats from day 0 (the early-treatment group) or a later-treatment group (from days 17 to 21). A scrambled peptide administrated with the same protocol served as a control. Results The modified peptide, but not the scrambled peptide, attenuated anti-GBM GN in both treatment groups, and halted further crescent formation even after disease onset. Kidneys from the modified peptide–treated rats exhibited reductions in IgG deposits, complement activation, and infiltration by T cells and macrophages. Treatment also resulted in an anti-inflammatory cytokine profile versus a proinflammatory profile for animals not receiving the modified peptide; it also reduced α 3-P14–specific T cell activation, modulated T cell differentiation by decreasing Th17 cells and enhancing the ratio of Treg/Th17 cells, and inhibited binding of α 3-P14 to antibodies and MHC II molecules. Conclusions A modified peptide involving alteration of a critical motif in a nephritogenic T cell epitope alleviated anti-GBM GN in a rat model. Our findings may provide insights into an immunotherapeutic approach for autoimmune kidney disorders such as Goodpasture disease.

Successful Treatment of Experimental Glomerulonephritis with Ides and Endos, Igg-Degrading Streptococcal Enzymes

Progress in Pathogenesis of Immunoglobin A Nephropathy

Endopeptidase Cleavage of Anti-Glomerular Basement Membrane Antibodies in vivo in Severe Kidney Disease: An Open-Label Phase 2a Study

Potent efficacy of an IgG-specific endoglycosidase against IgG-mediated pathologies

A Modified Peptide Derived from Goodpasture Autoantigen Arrested and Attenuated Kidney Injuries in a Rat Model of Anti-GBM Glomerulonephritis

New Treatment Strategies for IgA Nephropathy: Targeting Plasma Cells as the Main Source of Pathogenic Antibodies

New AAV vector targets glomerular endothelial cells

Protein A immunoadsorption for anti-glomerular basement membrane nephritis

Bacterial IgA protease-mediated degradation of agIgA1 and agIgA1 immune complexes as a potential therapy for IgA Nephropathy

Comparison of double filtration plasmapheresis with immunoadsorption therapy in patients with anti-glomerular basement membrane nephritis

Optimized synthesis, polymer conjugation, and proof-of-concept studies of the gd-IgA1 epitope for antibody-scavenging therapies in IgA nephropathy

Anti-glomerular Basement Membrane Glomerulonephritis: A Study in Real Life

New Horizons in IgA Nephropathy: A Focus on Current Treatment and Emerging Solutions

Sparsentan ameliorates glomerular hypercellularity and inflammatory-gene networks induced by IgA1-IgG immune complexes in a mouse model of IgA nephropathy

Staphylococcal Protein A Immunoadsorption for Anti-Glomerular Basement Membrane Diseases--report of Five Cases

Experimental Antiglomerular Basement Membrane GN Induced by a Peptide from <i>Actinomyces</i>

High-frequency plasma exchange therapy for immunocompromised, type I crescentic glomerulonephritis complicated with IgA nephropathy: A case report and literature review

Staphylococcal protein A immunoadsorption for Goodpasture's syndrome in four Chinese patients

High-Dose Immunoglobulin Therapy for Severe IgA Nephropathy and Henoch-Schonlein Purpura

State-of-Art Therapeutics in IgA Nephropathy

Rituximab for the treatment of refractory anti-glomerular basement membrane disease